Loading
3 standard-of-care settings across 2 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Stage I to III | Colectomy with regional lymphadenectomy; adjuvant FOLFOX or CAPOX for stage III and high-risk stage II, with ctDNA guidance under study. | 82 | ||
| MSI-H / dMMR | Mismatch-repair deficient, localised | Neoadjuvant nivolumab and ipilimumab (NICHE-2) and adjuvant atezolizumab with FOLFOX (ATOMIC) in trials. | 88 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| HER2 | Metastatic | As the colorectal page by sidedness and RAS, BRAF and HER2 status. | 98 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.